Percio Gulko, MD, joins Mount Sinai from North Shore-LIJ in Manhasset, New York where he served as Professor and Director of the Laboratory of Experimental Rheumatology at the Center for Genomics and Human Genetics at the Feinstein Institute for Medical Research. He was also a Professor of Molecular Medicine at Hofstra University and an Attending Physician in the Division of Rheumatology at North Shore University Hospital.
Dr. Gulko completed his medical degree, internship and clinical fellowship in Rheumatology at the Universidade Federal do Rio Grande do Sul. Porto Alegre in Brazil. He came to the United States as a research fellow in the Division of Rheumatology at the University of Alabama at Birmingham, and later completed his residency in Internal Medicine at the Medical College of Georgia in Augusta. He also completed a rheumatology fellowship at the National Institutes of Health, and was a faculty member at the Divisions of Autoimmune and Molecular Disease and Rheumatology at Columbia University’s College of Physicians and Surgeons before joining the Feinstein Institute.
Dr. Gulko has received numerous grants from the NIH, given lectures both nationally and internationally and has been published in leading peer-reviewed journals throughout the world. He serves on the editorial board of Genes and Immunity and Physiological Genomics and is a member of the American College of Rheumatology.
Multi-Disciplinary Training Areas
Biophysics and Systems Pharmacology [BSP], Genetics and Genomic Sciences [GGS], Immunology [IMM]Education
MD, Universidade Federal Do R.G.S.
Internship, Internal Medicine, Universidade Federal Do R.G.S.
Residency, Internal Medicine, Medical College of Georgia
Fellowship, Rheumatology, Universidade Federal Do R.G.S.
Fellowship, Rheumatology, National Institutes of Health
Fellowship, Rheumatology, Columbia University Medical Center
The Gulko Lab works on identifying new genes involved in the regulation of arthritis severity and joint damage. These new genes have the potential to become new prognostic biomarkers and new targets for more effective therapies for Rheumatoid Arthritis (RA) and other autoimmune diseases.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Gulko during 2017 and/or 2018. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting:
- Gerson Lehrman Group
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
- Oryn Therapeutics
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.